NVX 208

Drug Profile

NVX 208

Alternative Names: NVX-208

Latest Information Update: 15 Mar 2017

Price : $50

At a glance

  • Originator NuvOx Pharma
  • Developer NuvOx Pharma; University of Arkansas for Medical Sciences
  • Class Diagnostic agents; Fluorinated hydrocarbons; Fluorocarbons; Radiation-sensitising agents; Radiosensitisers; Small molecules
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Stroke

Most Recent Events

  • 06 Mar 2017 Phase-I/II clinical trials in Stroke in USA (IV)
  • 18 Aug 2016 The US FDA approves IND application for NVX 208 in Stroke
  • 18 Aug 2016 NuvOx plans a phase-Ib trial for Stroke in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top